Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued on Sunday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 3.3 %

Shares of NYSE BTX opened at $0.38 on Friday. The business has a fifty day simple moving average of $0.36 and a 200 day simple moving average of $1.00. The firm has a market capitalization of $22.26 million, a price-to-earnings ratio of -0.17 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.